Hoyoux C
Hémato-Oncologie pédiatrique, CHR Citadelle, Liège, Belgique.
Rev Med Liege. 2008 Jan;63(1):14-7.
Hemangioma is the most benign vascular tumor encountered in infancy; its incidence is 10-12% at 1 year of age. It usually appears a few weeks after birth, and rather rapidly grows until the age of 10-12 months; it then stabilizes and spontaneously regresses towards a complete disappearance over 5 - 10 years. Therefore, most hemangiomas need no treatment, but just a close clinical follow up. However, some hemangiomas (10-20% of cases), because of their location and/or complications, can have very serious aesthetic, functional, or even vital consequences: these require a more aggressive approach. A pharmacologic initial therapy based on high doses of corticosteroids or interferon alpha 2a or 2b has gained wide acceptance, but can entail serious side-effects. Vincristine represents a safe and effective treatment option for the management of those alarming hemangiomas.
血管瘤是婴儿期最常见的良性血管肿瘤；1岁时的发病率为10%-12%。它通常在出生后几周出现，并在10-12个月大之前迅速生长；然后稳定下来，并在5-10年内自行消退直至完全消失。因此，大多数血管瘤无需治疗，仅需密切临床随访。然而，一些血管瘤（10%-20%的病例），由于其位置和/或并发症，可能会产生非常严重的美学、功能甚至生命后果：这些需要更积极的治疗方法。基于高剂量皮质类固醇或干扰素α2a或2b的药物初始治疗已被广泛接受，但可能会带来严重的副作用。长春新碱是治疗那些令人担忧的血管瘤的一种安全有效的治疗选择。
